Introduction 

According to Acumen Research and Consulting, the global ovarian cancer diagnostics market is forecasted to grow at striking CAGR around 5.9 % over the forecast time frame and reach around US$ 1.8 billion by 2026.

One of the most prevalent kinds of cancer in females is ovarian cancer. It is a cancer which begins in the ovaries. Ovary is a woman reproductive organ that contains eggs or ova. There are two ovaries in the woman reproductive scheme: one on either side of the uterus. Hormones include progesterone and estrogen are produced by ovaries. Eggs are also produced by ovaries. Ovarian cancer can only be detected when it reaches the abdomen and pelvis. The ovarian cancer is more deadly and difficult to cure at this point. In the initial stage, it can be treated more effectively if it is limited to the ovarian cells.

The report provides analysis of global Ovarian Cancer Diagnostics market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year. 

Market Insights

The growing incidence and emphasis on early diagnosis & therapy of ovarian disease should boost business development.

As of 2018, all ovarian cancer had the largest mortality rate. It caused almost 14,000 fatalities in the United States in 2018. The illness has generic signs, including bloating, menstruation abnormality, vaginal swelling, indigestion and tiredness. No specific symptoms make it increasingly difficult to diagnose the disease early.  The prognosis of diseases continues low, since most patients are diagnosed in developed phases. So comprehensive study is essential to comprehend the biology of diseases so that efficient therapy choices are developed with the aim of overcoming opposition and minimizing toxicity. Further development of biomarkers could improve the identification of patients who require maintenance.

Factors such as an increase in government projects and financing for ovarian cancer research should fuel the industry. For example, the non-profit Ovarian Cancer Research Alliance (OCRA) focuses on the R&D of ovarian cancer. It promotes several study programs related to the diagnosis and therapy of this disease.

Some key factors restricting growth are lack of awareness of exact causative factors and late diagnosis of the disease. The fundamental molecular processes to recognize major genes or biochemical pathways that can be used for diagnosis & therapy are highly unmet. However, growing healthcare spending and technological advances create growth possibilities for the entire industry.

Cancer Type Stance

The sort of ovarian cancer depends on where cancer cells develop. In this section, epithel tumors stayed a precursor, representing more than 90 percent of all ovarian malignancies, in 2018. Serous, mucinous, endometrioid, or clear cell can be epithelial tumors. After the cancer has metastasized within the peritoneal nucleus, most individuals with epithelial cell carcinoma are identified. In the developed phase, 70% to 80% of people are diagnosed and the therapy choices and survival rate are reduced considerably. Collectively, germ and stromal cell tumors are capturing a lower share of this industry. Stromal cells grow in hormones such as estrogen, progesterone and testosterone in the organs accountable for generating them. Although common, germ cell tumors are most common in females between the ages of 20 and 30 years.

Diagnostic Type Stance

Due to the growing significance of early treatment and cancer staging, imaging methods accounted for the greatest share in 2018. The preliminary imaging technique for internally viewing and measurement of a tumor remains the transvaginal ultrasound. CT scans are chosen for the stadium of cancer, but are restricted to tiny tumors. Advanced imagery techniques, like MRI and PET, are used to detect metastases and severity of diseases.

The blood test industry is predicted to see steady growth in technology and increased customer consciousness throughout the forecast period. Ovarian cancer can contribute to high concentrations of some biomarkers that can function as tumor markers for diagnosis. For example, for this illness,CA-125 is the most prevalent blood exam. A greater market penetration for HER2, BRCA and KRAS mutation studies led to increased focus on genetic consulting and testing.

End Use Stance

The biggest share in 2018 was retained by end-use labs of Insights Hospital. This sector development can be ascribed to increased patient inflow for cancer treatment in clinics, increased customer consciousness and increased infrastructure expenditure in emerging and underdeveloped nations. Due to increased financing for cancer studies globally, the market for study institutes is anticipated to develop at the largest pace during the prediction era. The Fred Hutchinson Cancer Research Center, for example, is devoted to biomarkers and ovarian cancer screening.

Regional Stance

In North America, due to the powerful business performance of US ovarian diagnostics, accounted for over 45 percent of the total industry in 2018. Some other variables contributing to market growth in this region are favorable public policies, increased healthcare spending and the existence of important producers. During the forecast period Asia Pacific is anticipated to develop at the most high level because of variables such as general economic development, improved health infrastructure, increased disposable income and increasing customer consciousness. Ovarian cancer diagnostics are anticipated to grow rapidly in emerging countries like China, India and South Korea during the forecast period.

Market Segmentation

Global Ovarian Cancer Diagnostics Market, by Diagnosis Type

• Imaging
  • CT Scan
  • Ultrasound
  • PET Scan
  • MRI Scan
  • Others
• Biopsy
• Blood Test
  • BRCA
  • CA125
  • ER & PR
  • HER2
  • CEA
  • KRAS Mutation
  • Others
• Others

Global Ovarian Cancer Diagnostics Market, by Cancer Type

• Germ Cell Tumor
• Stromal Cell Tumor
• Epithelial Tumor
• Others

Global Ovarian Cancer Diagnostics Market, by End-use

• Cancer Diagnostic Centers
• Hospital Laboratories
• Research Institutes
• Others

Global Ovarian Cancer Diagnostics Market, by Geography

• North America.
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

The market research study on “Ovarian Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type, Diagnostics Type, End Use, By Region - Global Industry Size, Share, Trends and Forecast 2019 - 2026” offers detailed insights on global Ovarian Cancer Diagnostics market segments with market dynamics and their impact. The report also covers basic technology development policies.

This study offers an assessment of the recent sector trends in each subsection from 2015 to 2026 and forecasts income development at the worldwide, regional, and nation levels. ARC has divided the Ovarian Cancer Diagnostics market into the drug and region for the purpose of this research:

Key Players & Strategies

Some of the main competitors are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., AstraZeneca plc, Johnson & Johnson Services, Inc., Siemens Healthcare GmbH, Bio-Rad Technologies Inc., Thermo Fisher Scientific, and Abbott. Major competitors are increasingly concentrating on strategic activities such as launch & growth of products, combinations and purchases, licensing agreements and co-development agreements, making this industry extremely competitive. Foundation Medicine, for example, announced in June 2019 that it has obtained a FDA-approved extensive screening for genomic profiling for first-line maintenance treatment for BRCA-mutated metastatic ovarian cancer. This experiment can identify mutations of BRCA1/2 including germline and somatic mutations.

TABLE OF CONTENT